Search

Displaying results 8261 - 8270 of 10000 in total
  1. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid … Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  2. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency. … [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersProducts: Sogroya® 5 mg/1.5 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem (1 adet), SOGROYA® 5MG/1.5ML
  3. Drug

    Leridistim

    go.drugbank.com/drugs/DB15095
    Investigational

    Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).

  4. Drug

    Glutamine 2-n-15

    go.drugbank.com/drugs/DB15103
    Experimental

    Glutamine 2-n-15 is under investigation in clinical trial NCT01912235 (Arginine Synthesis in Healthy Adult Humans).

    Synonyms: Glutamine 2-n-15, L-(2-15N)GLUTAMINE
  5. Drug

    Ingenol disoxate

    go.drugbank.com/drugs/DB15109
    Investigational

    Ingenol disoxate is under investigation in clinical trial NCT02120456 (Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk

  6. Drug

    Onvansertib

    go.drugbank.com/drugs/DB15110
    Investigational

    Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).

    Synonyms: 1-(2-Hydroxyethyl)-8-((5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamideCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  7. Drug

    Utomilumab

    go.drugbank.com/drugs/DB15113
    Investigational

    Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

  8. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    Zolbetuximab (previously claudiximab)[A264748] is a chimeric cytolytic antibody comprising variable regions derived from mouse anti-human claudin-18 isoform 2 monoclonal antibody and constant regions derived … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas

  9. Drug

    PF-05241328

    go.drugbank.com/drugs/DB15124
    Investigational

    PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound

  10. Drug

    Belapectin

    go.drugbank.com/drugs/DB15125
    Investigational

    Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).